 MS147 is a novel compound that targets the BMI1 and Ring1B proteins, two key components of the Polycomb Repressive Complex 1, PRC1. This compound works by binding to the EED protein, which then binds to both BMI1 and Ring1B. The EED-BMI1-Ring1B complex is then broken down by the enzyme DHL, resulting in the degradation of these proteins. This process leads to a decrease in the amount of H2AK119ab, a type of histone modification associated with the silencing of genes, and thus prevents the formation of tumors. Additionally, MS147 has been shown to be effective against cancer cells that are resistant to other treatments, suggesting that it could be used as a potential therapy for certain types of cancer. This article was authored by Kwang Soo Park, Lee Hwai Chin, M.D. Kabir, and others.